Last reviewed: May 1, 2026
Free Guide · Blue Goat Cyber · Updated 2026
CHECKLIST · 1 PAGE · PROSPECT RESOURCE
Cost-of-Delay (Next-Quarter Edition) What a one-quarter cybersecurity pause actually does to your FDA timeline.
Pushing the cybersecurity workstream out by a single quarter rarely saves a quarter of work - it usually compresses the same scope into less time, on the wrong side of the submission deadline.
Schedule impact
Is your submission target inside a 6-month window?
Will a 90-day cyber pause overlap design freeze or V&V?
Does a quarter-long delay push you past a payer or pilot commitment? Have you confirmed FDA reviewer availability for your submission window?
Scope & rework risk Will architecture decisions made this quarter need a threat model later? Are you writing code today that an SBOM and VEX will need to cover? Is anyone tracking third-party CVEs that will need to be triaged at submission time? Are postmarket monitoring obligations under Section 524B(b) being scoped in parallel?
How to read it. Three or more boxes checked means a quarter of delay almost certainly translates into a quarter of submission slip - and usually more, because the work compounds.
NEXT STEP → Book a 20-minute call to map your timeline against the cyber deliverables FDA expects in the eSTAR. Book your discovery call: go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session
Page 1 · © Blue Goat Cyber · 250+ FDA submissions, zero rejections, since 2014
Talk to us
This guide is part of Blue Goat Cyber's MedTech cybersecurity library. To apply it to your device program, book a 30-minute strategy session - no cost, no obligation. Or browse all guides.
